《睡眠專業人士雜誌》
星期四, 七月 23, 2026
Treating obstructive sleep apnea (OSA) is at an exciting crossroads where therapeutic advances are coming of age in the era of precision medicine. In the past, the only option was continuous positive airway pressure (CPAP) therapy. Now, there are many effective alternatives to manage sleep apnea and even more on […]
Sleep Pharmaceutical Update Nov/Dec 2024 Eight abstracts presenting data from across the sleep portfolio of Jazz Pharmaceuticals plc were featured at the 37th annual Psych Congress, held Oct. 29–Nov. 2, 2024 in Boston. That data included topline results of the Phase 4 DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) trial, […]
Eli Lilly and Company announced the U.S. Food and Drug Administration (FDA) approved Zepbound® (tirzepatide) as the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity.1 Zepbound may help adults with moderate-to-severe obstructive sleep apnea and obesity improve their sleep disorder. It should be used with […]
P4 medicine is an evolving approach to personalized medicine that involves four key elements of care: 1) predicting who will develop disease and comorbidities, 2) preventing rather than reacting to disease, 3) personalizing diagnosis and treatment, 4) having patients participate in their own care.1 This approach is gaining traction in […]
Avadel Pharmaceuticals plc , a biopharmaceutical company focused on transforming medicines to transform lives, announced that yesterday, the U.S. District Court for the District of Columbia (“Court”) ruled in favor of the Food and Drug Administration (“FDA”) in a suit brought by Jazz Pharmaceuticals Inc. (“Jazz”) under the Administrative Procedure […]
Avadel Pharmaceuticals plc announced today that the U.S. Food and Drug Administration (FDA) has approved its supplemental new drug application (sNDA) for LUMRYZ for the treatment of cataplexy or EDS in patients 7 years of age and older with narcolepsy. “This approval represents an important milestone for the narcolepsy community, […]
The Slow Wave DS8™ oral appliance therapy (OAT), initially FDA-cleared for the prescription treatment of obstructive sleep apnea (OSA) in 2021 (K191320), has now been dually cleared by the FDA for the treatment of sleep bruxism (K240463). This makes the Slow Wave DS8, now marketed as BROSA™ when sold as […]
Axsome Therapeutics, Inc. announced that it has reached an agreement with Sandoz Inc. (Sandoz) to dismiss the patent litigation related to Axsome’s product Sunosi® (solriamfetol). The litigation, which was pending in the United States District Court for the District of New Jersey, resulted from submission by Sandoz of an Abbreviated New Drug […]
There has been an increasing number of studies looking at orofacial myofunctional therapy (OMT) as a promising adjunctive treatment for obstructive sleep apnea (OSA).1 OMT essentially helps the patient to retrain the muscles around the face, mouth, and tongue to establish correct oral rest posture and functioning of the oral […]
ProSomnus Sleep Technologies announced record revenues for the quarter that ended 六月 30, 2024, as it formally emerged from reorganization on 八月 5, 2024. Revenues for the second quarter totaled a record $9.1 million reflecting increasing orders for the Company’s precision intraoral medical devices. These quarterly results reflect a 22% […]
